Tofisopam: Clinical Profile and Usage
Tofisopam is an atypical anxiolytic agent with a 2,3-benzodiazepine structure that differs fundamentally from classical 1,4-benzodiazepines—it provides anxiolytic effects without significant sedation, muscle relaxation, cognitive impairment, or withdrawal symptoms, making it a safer alternative for anxiety management where available.
Indications
Tofisopam is primarily indicated for:
- Generalized anxiety disorder 1
- Lower urinary tract symptoms (off-label) 2
- Emerging evidence suggests potential benefits for cognitive enhancement and antidepressant-like effects 3, 4, though these remain investigational
The drug demonstrates comparable anxiolytic efficacy to diazepam but with a markedly superior safety profile 1.
Dosing Regimen
Standard dosing:
- 50 mg three times daily (150 mg total daily dose) 1, 2
- Treatment duration: minimum 2 weeks for therapeutic effect 1, 2
- Higher doses (100-200 mg single doses) have been studied but standard clinical practice uses 50 mg TID 5
Key dosing considerations:
- No dose tapering required upon discontinuation—withdrawal symptoms are minimal and comparable to placebo 1
- Can be used in patients requiring CYP3A4 substrates, but monitor closely as tofisopam inhibits CYP3A4 with an IC50 of 0.8 micromol/L 6
- Dose adjustments may be needed when co-administered with immunosuppressants or other CYP3A4 substrates 6
Contraindications and Precautions
Drug interactions requiring caution:
- CYP3A4 substrates (immunosuppressants, certain statins, calcium channel blockers): Tofisopam inhibits CYP3A4 enzyme activity in a dose-dependent manner, potentially increasing blood levels of these medications 6
- Monitor immunosuppressant levels closely if co-administration is necessary; dose reduction of the substrate drug or discontinuation of tofisopam may be required 6
Unlike classical benzodiazepines, tofisopam does NOT:
- Bind to benzodiazepine receptors 5
- Cause significant sedation or psychomotor impairment 5
- Impair cognitive function 1, 5
- Produce clinically significant withdrawal symptoms 1
Adverse Effects
Common adverse effects (minimal):
- Dry mouth/thirst: reported in only 3% of patients 2
- Adverse effects occur significantly less frequently than with diazepam 1
Notable absence of typical benzodiazepine side effects:
- No EEG changes 5
- No sedation or psychological impairment 5
- No muscle relaxation 7
- Mild stimulant effect may be apparent on subjective ratings 5
Mechanism of Action
Tofisopam's unique pharmacological profile stems from its atypical mechanism:
- Does not bind to classical benzodiazepine receptors 5
- Exhibits mixed dopamine agonist/antagonist properties 7
- May enhance coping ability rather than producing tranquilization 7
- Modulates serotonergic, catecholaminergic, and opioidergic systems (μ- and δ-opioid receptors) 3
- Enhances hippocampal synaptogenesis, neurogenesis, and glial plasticity 4
Clinical Advantages Over Classical Benzodiazepines
Tofisopam should be strongly considered when:
- Anxiolytic therapy is needed but sedation must be avoided
- Cognitive function preservation is critical
- Long-term treatment is anticipated (no tolerance or dependence issues)
- Patient operates machinery or drives regularly
- Risk of benzodiazepine abuse or dependence is a concern
The drug represents a fundamentally different class of anxiolytic that reduces anxiety by enhancing coping mechanisms rather than through tranquilization 7, making it particularly valuable for functional anxiety management in ambulatory patients.
Important limitation: Tofisopam is not available in the United States or Canada but is used in approximately 30 countries worldwide 1.